Pharmacotherapy of social anxiety disorder
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Social anxiety disorder (SAD) is one of the most common psychiatric disorders, with a lifetime prevalence of 5-12%. Fears of scrutiny and embarrassment in social and public situations are accompanied by anxiety symptoms, avoidance behavior, and impairment in social and work functioning. Several classes of medication, as well as cognitive-behavioral therapies, have evidence for efficacy in the treatment of SAD, but only a minority of individuals with the disorder receives treatment. AREAS COVERED: This review focuses on the evidence-based treatment of SAD with medications including serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, other antidepressants, benzodiazepines, alpha-delta calcium-channel agents, and beta-adrenergic blockers. It discusses clinical considerations in the selection and monitoring of treatments, including issues of safety, duration of treatment, comorbidity, and integration of medication with psychotherapeutic treatment. For this review, a PubMed literature search was conducted during July, 2010. EXPERT OPINION: Medications in several classes have been demonstrated efficacious in the treatment of SAD. Treatment selection and implementation require attention to clinical diagnosis, patient education, and appropriate monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
The etiology of social phobia: empirical evidence and an initial model
Rapee, R. M., & Spence, S. H. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.06.004 · Cited by 693
Grant, B. F., Hasin, D. S., Blanco, C., Stinson, F. S., Chou, S. P., Goldstein, R. B., Dawson, D. A., Smith, S., Saha, T. D., & Huang, B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1102 · Cited by 601
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Self-citationClark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · cited 2×
“In a comparison of CBT to fluoxetine + self-exposure and placebo + self-exposure, after 16 weeks, there were significant improvements from all three treatments, but CBT was superior to both medication and placebo at post-treatment and 12-month follow-up, whereas fluoxetine did not differ from placebo [23].”
BackgroundAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“Patients who had received D-cycloserine showed significantly greater improvement on self-report measures than those who had received placebo, and this superior response was maintained 1 month after treatment had ended [77].”
BackgroundPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 2×
“The irreversible MAOI phenelzine, at doses of 30 -- 90 mg/day, has appeared effective for SAD in four controlled trials [35], and this efficacy was confirmed in a recent meta-analysis (n = 3 studies; RR = 2.”
BackgroundSelf-citationFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 1×
“Another study compared a different form of CBT to fluoxetine, placebo, and their combinations (CBT/fluoxetine and CBT/placebo) in a large, multisite sample of individuals with generalized SAD [73].”
BackgroundCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 2×
“Some other comparative studies have limited importance for understanding relative efficacy because they compared CBT to medications that were not themselves superior to placebo [48,56], or modified the CBT procedure such that its efficacy may have been reduced [45].”
Background
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioara, F. L., Toma, M. M., Bungau, S., & Bumbu, A. G. (2021) · Molecules · doi:10.3390/molecules26123724 · Cited by 317
Should OCD be classified as an anxiety disorder in DSM-V?
Stein, D. J., Fineberg, N. A., Bienvenu, O. J., Denys, D., Lochner, C., Nestadt, G., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2010) · Depression and Anxiety · doi:10.1002/da.20699 · Cited by 212
SOCIAL ANXIETY DISORDER IN DSM-5: Review: Social Anxiety Disorder in DSM-5
Heimberg, R. G., Hofmann, S. G., Liebowitz, M. R., Schneier, F. R., Smits, J. A. J., Stein, M. B., Hinton, D. E., & Craske, M. G. (2014) · Depression and Anxiety · doi:10.1002/da.22231 · Cited by 166
Self-citationAlkhalifa, A. E., Alkhalifa, O., Durdanovic, I., Ibrahim, D. R., & Maragkou, S. (2025) · Journal of Dementia and Alzheimer's Disease · doi:10.3390/jdad2020017 · Cited by 66
Metadata
- Authors
- Schneier, F. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-01-18
- Volume
- 12
- Issue
- 4
- Pages
- 615-625
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2075736632
- Cited by
- 41
- References
- 28
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy of social anxiety disorder. https://app.cochat.ai/papers/10.1517/14656566.2011.534983
- The paper
- Schneier, F. R. (2011). Pharmacotherapy of social anxiety disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2011.534983
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.